Key result
Treatment with the AMPA receptor positive allosteric modulator CX516 significantly ameliorated novelty-induced hyperactivity and increased rearing in Scn2a haploinsufficient mice.
Why the study?
Causal relationships and pathogenic mechanisms underlying neurological defects associated with SCN2A mutations, especially social and psychiatric features, remain to be elucidated.
In a mouse model of Scn2a haploinsufficiency, treatment with the ampakine CX516 rescued exploratory hyperactivity, suggesting a potential therapeutic strategy for related neurological disorders.
Answers are grounded in this paper and cite their sources.
May inform therapy development for SCN2A-related disorders; hypothesis-generating from animal data and requires clinical validation.
Mutations of the SCN2A gene encoding a voltage-gated sodium channel alpha-II subunit Nav1.2 are associated with neurological disorders such as epilepsy, autism spectrum disorders, intellectual disability, and schizophrenia. However, causal relationships and pathogenic mechanisms underlying these neurological defects, especially social and psychiatric features, remain to be elucidated. We investigated the behavior of mice with a conventional or conditional deletion of Scn2a in a comprehensive test battery including open field, elevated plus maze, light-dark box, three chambers, social dominance tube, resident-intruder, ultrasonic vocalization, and fear conditioning tests. We further monitored the effects of the positive allosteric modulator of AMPA receptors CX516 on these model mice. Conventional heterozygous Scn2a knockout mice (Scn2aKO/+) displayed novelty-induced exploratory hyperactivity and increased rearing. The increased vertical activity was reproduced by heterozygous inactivation of Scn2a in dorsal-telencephalic excitatory neurons but not in inhibitory neurons. Moreover, these phenotypes were rescued by treating Scn2aKO/+ mice with CX516. Additionally, Scn2aKO/+ mice displayed mild social behavior impairment, enhanced fear conditioning, and deficient fear extinction. Neuronal activity was intensified in the medial prefrontal cortex of Scn2aKO/+ mice, with an increase in the gamma band. Scn2aKO/+ mice exhibit a spectrum of phenotypes commonly observed in models of schizophrenia and autism spectrum disorder. Treatment with the CX516 ampakine, which ameliorates hyperactivity in these mice, could be a potential therapeutic strategy to rescue some of the disease phenotypes.
No takes yet. Share an insight, caveat, or question.
Tatsukawa et al. (2019) studied Scn2a haploinsufficiency (Autism and Schizophrenia model). CX516 vs. Vehicle (saline) was evaluated on Locomotor activity (distance traveled) and rearing in open field test (p=<0.001). Treatment with the AMPA receptor positive allosteric modulator CX516 significantly ameliorated novelty-induced hyperactivity and increased rearing in Scn2a haploinsufficient mice.
Synapse has enriched 10 related papers. Consider them for comparative context: